Pierre Armand Morgon

Pierre Armand Morgon

Chairman at EUROCINE VACCINES AB

Net worth: 25 519 $ as of 2024-04-29

61 year
Health Technology
Consumer Services
Commercial Services

Profile

Dr. Pierre Armand Morgon is a Chairman at Kupando GmbH, a Non-Executive Chairman at Adiposs SA, a Chairman at MYCB1 BV, a Chairman at MYCB1 Group BV, an Independent Non-Executive Director at Barinthus Biotherapeutics Plc, a CEO and Founder at Mrgn Advisors, a Chairman at Eurocine Vaccines AB, a CEO at Drug Abuse Sciences, an Advisor at CUBE Labs Srl, a Chairman at Health Technology Holding Srl, a Chief Executive Officer & Manager at MRGN Advisors SARL and an Independent Non-Executive Director at Limula SA. He is on the Board of Directors at Amoéba SA, Univercells SA, Barinthus Biotherapeutics Plc and Limula SA. Dr. Morgon was previously employed as an Executive VP-Portfolio Strategy & Head-Europe by CanSino Biologics, Inc., a Non-Executive Director by Vaccitech Ltd., a Chairman by Alma Biotherapeutics, a Chairman by Virometix AG, a Chief Executive Officer by AJ Biologics Sdn.
Bhd., a Chairman by Theradiag SA, a VP-Franchise & Global Marketing Strategy by Sanofi Pasteur, a Chief Operating Officer by Onxeo SA, and a Marketing Director by Cegedim SA. He also served on the board at Schering-Plough SAS.
He received his undergraduate degree from INSEAD, an undergraduate degree from the International Institute for Management Development, a graduate degree from Jean Moulin University Law School, an MBA from ESSEC Business School and a doctorate degree from the University of Lyon.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2024-05-09 10,506 ( 0.03% ) 25 519 $ 2024-04-29

Pierre Armand Morgon active positions

CompaniesPositionStart
EUROCINE VACCINES AB Chairman 2019-05-31
AMOÉBA Director/Board Member 2020-12-16
BARINTHUS BIOTHERAPEUTICS PLC Director/Board Member 2017-12-31
Drug Abuse Sciences Chief Executive Officer 2005-12-31
Director/Board Member -
Consultant / Advisor -
Chairman 2021-11-30
MYCB1 BV Chairman 2020-06-30
MRGN Advisors SARL Chief Executive Officer -
░░░░░░░ ░░ ░░░░░░░░ -
░░░░░ ░░░░░ ░░ ░░░░░░░░ ░░░░░░░░░░
All active positions of Pierre Armand Morgon

Former positions of Pierre Armand Morgon

CompaniesPositionEnd
░░░░░░░░░ ░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░ ░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░
░░ ░░░░░░░░░ ░░░░ ░░░░ ░░░░░ ░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░ ░░░░░ ░ ░░░░░░░░░ ░░░░░░░░░░
See the detail of Pierre Armand Morgon's experience

Training of Pierre Armand Morgon

University of Lyon Doctorate Degree
ESSEC Business School Masters Business Admin
Jean Moulin University Law School Graduate Degree
INSEAD Undergraduate Degree
International Institute for Management Development Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Pierre Armand Morgon's experience

Connections

88

1st degree connections

29

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies6
EUROCINE VACCINES AB

Health Technology

CEGEDIM

Technology Services

CANSINO BIOLOGICS INC.

Health Technology

AMOÉBA

Consumer Non-Durables

BARINTHUS BIOTHERAPEUTICS PLC

Health Technology

VALERIO THERAPEUTICS

Health Technology

Private companies18

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Alma Biotherapeutics

Mrgn Advisors

MYCB1 Group BV

Health Technology

MRGN Advisors SARL

MYCB1 BV

Health Technology

Finance

Commercial Services

Health Technology

Health Technology

Drug Abuse Sciences

Finance

See company connections
  1. Stock Market
  2. Insiders
  3. Pierre Armand Morgon